ENSC VS PXMD Stock Comparison

Performance

ENSC
10/100

ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

PXMD
10/100

PXMD returned -91.68% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

ENSC
25/100

ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

PXMD
25/100

PXMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

ENSC
33/100

ENSC has missed earnings 3 times in the last 20 quarters.

PXMD

"Earnings" not found for PXMD

Profit

ENSC
27/100

Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.

PXMD
24/100

Out of the last 16 quarters, PXMD has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

ENSC
50/100

ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

PXMD
55/100

PXMD has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ensysce Biosciences, Inc. Common Stock Summary

Nasdaq / ENSC

Healthcare

Biotechnology

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

PaxMedica, Inc. Common Stock Summary

Nasdaq / PXMD

Healthcare

Biotechnology

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

Power up your portfolio